Trial · NCT07025330
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 40
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Change in T2 mapping of pancreas on MRI | From Baseline to Week 12 | |
| Secondary | Change in extracellular volume (ECV) of pancreas on MRI | From Baseline to Week 12 | |
| Secondary | Change in microvascular perfusion fraction of pancreas on MRI | From Baseline to Week 12 | |
| Secondary | Change in serum IgG4 level | From Baseline to Week 12 | |
| Secondary | Change in serum IgG level | From Baseline to Week 12 | |
| Secondary | Change in serum IgE level | From Baseline to Week 12 | |
| Secondary | Change in plasmablast count | From Baseline to Week 12 | |
| Secondary | Change in absolute regulatory B cell count | From Baseline to Week 12 | |
| Secondary | Change in IgG4-RD Responder Index | From Baseline to Week 12 | |
| Secondary | Change in physician global assessment of disease | From Baseline to Week 12 | Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state. |
| Secondary | Change in patient global assessment of disease | From Baseline to Week 12 | Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state. |
| Secondary | Change in patient global assessment of ocular symptoms | From Baseline to Week 12 | Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state. |
| Secondary | Change in patient global assessment of salivary symptoms | From Baseline to Week 12 | Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state. |
| Secondary | Change in FACIT-F fatigue score | From Baseline to Week 12 | Total score range: 0-52, lower scores correspond with more fatigue. |
| Secondary | Change in C3 laboratory assessment | From Baseline to Week 12 | |
| Secondary | Change in C4 laboratory assessment | From Baseline to Week 12 | |
| Secondary | Change in total IgG laboratory assessment | From Baseline to Week 12 | |
| Secondary | Change in ESR laboratory assessment | From Baseline to Week 12 | |
| Secondary | Change in CRP laboratory assessment | From Baseline to Week 12 | |
| Secondary | Number of participants with safety endpoints of interest | From Screening to end of follow-up at Week 18 | Safety endpoints of interest include hypogammaglobulinemia, severe infection requiring hospitalization or IV antibiotics, and mortality |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07025330/registered?page=2